MK-5442

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

OsteoporosisPostmenopausal Osteoporosis

Phase 2

A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)

TerminatedNCT00960934

Merck Sharp & Dohme LLCOsteoporosis

Start: 2009-10-31End: 2010-12-31Updated: 2015-02-18

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

CompletedNCT00996801

Merck Sharp & Dohme LLCOsteoporosis, Postmenopausal Osteoporosis

Start: 2009-11-30End: 2011-06-30Updated: 2016-01-22

Related Papers

Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis.

2021-02-193 citations